IV-255 is a selective small molecule inhibitor of the BRG1 bromodomain, heightening DNA damage when administered with Temozolomide and Bleomycin. It also curtails the invasiveness of GBM cells and augments both Temozolomide-induced cell death and Temozolomide's apoptosis-inducing activity (1).